Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: chemotherapy + can + blood  Related to the article below (Last Update: 5/12/2008)

A malady with no treatment?
National Post, Canada -
When a judge in Hamilton ordered a young cancer patient to undergo chemotherapy last week, she triggered a bitter confrontation between the child's parents ...
Beat cancer by taking your life in your hands
Scotsman, United Kingdom -
Although doctors were able to operate successfully, this delay meant he faced six months of gruelling chemotherapy. He said: "Had I been diagnosed quicker, ...
Load your plate with plant foods to help fight cancer ic Wales
all 5 news articles »
Diagnosis: Cancer, but Hope Evolving
RedOrbit, TX -
Tamoxifen, an anti-hormone pill, can be given to patients after breast cancer surgery or chemotherapy to reduce the risk of the cancer spreading to other ...
Emporia infant battling leukemia
Emporia Gazette, KS -
Mariana has gone through her first round of chemotherapy and as of last week was on pain medications to keep her comfortable as she was in a lot of pain, ...
In Delusions of Romance, Genuine Comfort
New York Times, United States -
When she grew too weak from chemotherapy and radiation to live alone ? much less move the furniture ? she was transferred to a rehabilitation facility. ...

Seattle Post Intelligencer
$7000 spent to try to save Trudy's life a bargain
Seattle Post Intelligencer -
Radiation and chemotherapy could stave off the cancer, but not cure it. Just before Thanksgiving, after a consultation with Sarbu and the folks at WSU, ...
The many moods of sexual dysfunction
Jamaica Observer, Jamaica - May 11, 2008
... and chemotherapy drugs), diseases (such as diabetes or high blood pressure), excessive alcohol use or vaginal infections can cause sexual problems. ...

Hindu
Tragedies and a public triumph
Hindu, India - May 10, 2008
?The chemotherapy has made him very weak. We do not know if he will need another transplant,? says Parthasarathy Chakravarthy, his father. ...

Geelong Advertiser
Laura Hebb aims to get back to school
Geelong Advertiser, Australia -
Laura is still receiving chemotherapy and has spent a mere 45 minutes at school this year. During January and February she rarely got to spend any time at ...
Broncos Player Helps Toddler With Leukemia
cbs4denver.com, CO -
For those who can't afford to make a donation, they can help Quentin and other children with leukemia and various types of cancer by making a blood ...
Source: Google News

… in remission blood samples of all patients with t (8; 21) acute myeloid leukemia after chemotherapy … -
R Kusec, K Laczika, P Knobl, J Friedl, H Greinix, … - Leukemia, 1994 - ncbi.nlm.nih.gov
AML1/ETO fusion mRNA can be detected in remission blood samples of all patients
with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone ...

Fighting cancer by attacking its blood supply -
J Folkman - Sci Am, 1996 - sciamdigital.com
... off, allowing the metastases to expand (right) as blood vessels (red ... Nevertheless,
primary tumors should be removed; follow-up chemotherapy can prevent the ...

… Marrow Mesenchymal Stem Cells in Advanced Breast Cancer Patients Receiving High-Dose Chemotherapy -
ON Koc, SL Gerson, BW Cooper, SM Dyhouse, SE … - Journal of Clinical Oncology, 2000 - jcojournal.org
... We recovered clonogenic MSCs from peripheral blood in 13 ... these relatively large cells
can traverse the ... indicates that high-dose chemotherapy?related stromal ...

Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. -
PL Simonian, DA Grillot, G Nunez - Blood, 1997 - ncbi.nlm.nih.gov
Blood. 1997 Aug 1;90(3):1208-16. Click here to read Bcl-2 and Bcl-XL can
differentially block chemotherapy-induced cell death. Simonian ...

Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human …
LS Schwartzberg, R Birch, B Hazelton, KW Tauer, P … - J Hematother, 1992 - ncbi.nlm.nih.gov
... Chemotherapy can serve as a stimulus for mobilizing hematopoietic progenitor
cells to the peripheral blood for harvest via leukapheresis. ...

… fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as … -
IF Khouri, M Keating, M Korbling, D Przepiorka, P … - Journal of Clinical Oncology, 1998 - jco.ascopubs.org
... Transplant-lite: induction of graft-versus-malignancy using fludarabine- based
nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as ...

The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. -
N Uchida, D He, AM Friera, M Reitsma, D Sasaki, B … - Blood, 1997 - ncbi.nlm.nih.gov
... with a combination of cytokines and chemotherapy can effectively stimulate the release
of hematopoietic stem cells (HSC) into the peripheral blood (PB), which ...

Reconstitution of Hematopoiesis after High-Dose Chemotherapy by Autologous Progenitor Cells … -
W Brugger, S Heimfeld, RJ Berenson, R Mertelsmann, … - New England Journal of Medicine, 1995 - content.nejm.org
... Background Autologous peripheral-blood progenitor cells can restore hematopoiesis
after high-dose chemotherapy in patients with solid tumors or hematologic ...

Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute … -
NPG Contact - Leukemia, 2003 - nature.com
... Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly
diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts ...

… Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus- … -
S Giralt, E Estey, M Albitar, K van Besien, G … - Blood, 1997 - bloodjournal.hematologylibrary.org
... of 15 patients cleared their peripheral blood blasts ... engraftment of donor hematopoietic
cells can be achieved after standard-dose chemotherapy, it may ...

Source: Google Scholar

Temporary Improvement Of Tumor Blood Flow Can Improve Chemotherapy
A treatment for neuroblastoma that lands a one-two punch works best when the second punch is timed to take maximum advantage of the first one, according to results of studies at St. Jude Children's Research Hospital. Neuroblastoma is a pediatric solid tumor that arises from cells in the peripheral nervous system.

The finding holds promise for improving neuroblastoma treatment by using the drug bevacizumab to block VEGF, a protein that stimulates blood vessel growth in tumors and then following with the chemotherapy drug topotecan, which depends on blood vessels to penetrate the tumor and kill the cancer cells. A report on this work appears in the current issue of Clinical Cancer Research.
Results of the current study are especially important because drugs such as bevacizumab are being evaluated in clinical trials for children with neuroblastoma. However, there are no standard guidelines for how much of the drug to give or when to give it. Such guidelines would be especially helpful for developing combination therapy with both bevacizumab and chemotherapy drugs, not only for neuroblastoma, but also for other tumors.

"The results of our study are a significant step toward establishing such guidelines," said Andrew Davidoff, M.D., director of surgical research at St. Jude, and the report's senior author.

The St. Jude team based their strategy on previous findings that suggested blocking VEGF at first improves the tumor's vasculature, or blood vessel system, by eliminating weak and faulty vessels, while temporarily sparing healthy, normal blood vessels. The investigators reasoned that if they treated tumors with bevacizumab first, the temporarily improved tumor circulation would more efficiently deliver topotecan but only if they timed this one-two punch correctly.

"A growing tumor releases VEGF to stimulate growth of the blood vessels that support its own growth," Davidoff said. "But much of this new vasculature is poorly constructed and leaks fluid into the spaces around the cancerous cells, increasing the pressure inside the tumor. This increased pressure outside the vasculature acts like a wall to prevent cancer drugs from passing through the blood vessels."

Bevacizumab eliminates the shoddy vasculature, temporarily sparing the more sturdily built vessels, which do not leak fluid, but deliver the drug throughout the tumor, Davidoff said.

Davidoff's team first treated mouse models that carried transplanted human neuroblastomas with a single dose of bevacizumab. They studied the changes in the tumor vasculature at different times after treatment with a single dose of bevacizumab; finally, they studied how well topotecan penetrated the tumor and inhibited its growth when given at different intervals after bevacizumab.
The researchers showed that bevacizumab reduced the density of the tumor's vasculature to less than 30 percent of that in untreated tumors within seven days, accompanied by a significant decrease in pressure in the tumor caused by fluid passing through from the blood vessels. The remaining, normalized vasculature perfused the tumor more thoroughly than before treatment with bevacizumab; and the amount of topotecan it carried throughout the tumor was about 80 percent more when given one to three days after bevacizumab compared to when both drugs were given either at the same time or seven days apart.

When the researchers administered topotecan to the tumor-bearing mice three days after bevacizumab, the size of the tumors was only 36 percent of the size of untreated tumors, compared to 88 percent when mice were treated with bevacizumab alone; 54 percent when treated with topotecan alone; and 44 percent when tumor-bearing mice were treated with both drugs at the same time.

"We observed in the mouse model of neuroblastoma that the maximum amount of topotecan reached the tumor and had maximum tumor-reducing effect if we waited three days after administering bevacizumab," Davidoff said. "This suggested that combination treatment of children with neuroblastoma should take into account that there is a window of opportunity for improving topotecan delivery after treatment with bevacizumab. Further studies should tell us how long that window is open."

Other authors of the study include Paxton Dickson, John Hamner, Thomas Sims, Charles Fraga, Catherine Ng, Surender Rajasekeran, Nikolaus Hagedorn, M. Beth McCarville and Clinton Stewart.

This work was supported in part by the Alliance for Cancer Gene Therapy, the Assisi Foundation of Memphis, the U.S. Public Health Service Childhood Solid Tumor Program, a Cancer Center Support Grant from the National Cancer Institute and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit http://www.stjude.org.

St. Jude Children's Research Hospital
332 N. Lauderdale St., Mail Stop 761
Memphis, TN 38122
United States
http://www.stjude.org
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.